1.. Resource utility {#S1}
====================

The AD-HIES hiPSC lines and their derivatives could be used for *in vitro* disease modeling to better elucidate the pathophysiology of AD-HIES. These cells could help clarify the effects of the *STAT3* mutation in developmental processes as well as differentiation and proliferation of various cell types *in vitro*.

2.. Resource Details {#S2}
====================

Hyperimmunoglobulin syndromes (HIES) consist of a group of rare primary immune deficiency disorders characterized by elevated immunoglobulin E levels, eczema, and recurrent pulmonary and skin infections ([@R2]). Both autosomal dominant and recessive patterns of inheritance have been reported in HIES with autosomal dominant (AD-HIES) patterns being more common. In addition to immunodeficiency, patients experience severe non-immunological features including skeletal, connective tissue and vascular abnormalities, poor post-infection healing and subsequent pulmonary failure ([@R1]). AD-HIES is caused by dominant negative mutations in the signal transducer and activator of the transcription factor 3 *(STAT3)* gene ([@R3]; [@R5]). Despite the identified genetic cause of the disease, the exact mechanisms of the AD-HIES pathologies are not well understood, preventing the development of specific therapies and limiting treatment options to general antimicrobial prophylaxis and multidisciplinary care.

In our study, skin punch biopsy samples from 3 patients with AD-HIES were collected at the NIH Clinical Center in addition to a complete medical history and physical exam including clinical onset, demographics and other phenotype specific details ([Table 1](#T1){ref-type="table"}). As with standard control iPSCs lines, AD-HIES iPSCs were able to maintain pluripotency over 60 passages as determined by morphological observations and the expression of typical pluripotency markers, OCT4, NANOG, TRA-1--60 and SSEA4 ([Fig 1A](#F1){ref-type="fig"}). Genotyping of hiPSC identified either an SH2 domain or a DNA binding domain mutation in all the clones (total of 3) shown in [Fig 1B](#F1){ref-type="fig"}. To test the differentiation potential of the three cell lines, we performed embryoid body formation assays that drive the cells toward differentiation into the three primary germ layers *in vitro.* The expression of the endoderm *(AFP),* ectoderm *(NESTIN)* and mesoderm *(RUNX1)* signature genes was determined with real-time (RT) PCR, which showed upregulated expression levels in AD-HIES lines after differentiation ([Fig 1C](#F1){ref-type="fig"}). All generated cell lines demonstrated chromosomal stability and a normal karyotype ([Fig 1D](#F1){ref-type="fig"}). [Table 2](#T2){ref-type="table"} summarizes the characterization and validation of AD-HIES hiPSCs. In addition, short tandem repeat (STR) profiles confirmed that all iPSC lines matched their parental fibroblasts completely in 15 amplified STR loci ([supplement 1](#SD1){ref-type="supplementary-material"}). All cultures were routinely tested for mycoplasma contamination and were found to be negative ([supplement 2](#SD2){ref-type="supplementary-material"}). To the best of our knowledge, this is the first published study to generate iPSC lines from AD-HIES patients.

3.. Materials and methods {#S3}
=========================

3.1.. Subjects and study approval {#S4}
---------------------------------

Unrelated patients with clinical evidence of AD-HIES and confirmed *STAT3* mutations were consented to NHLBI IRB approved study 10-H-0126.

3.2.. Derivation of patient-specific fibroblasts {#S5}
------------------------------------------------

Fibroblasts lines were generated from punch skin biopsies as previously described ([@R4]). Briefly, the sample was cut into 1 mm pieces and digested for 1h at 37°C in 0.1% Collagenase Type II/0.25 U/ml Dispase (both from Thermo Fisher Scientific)/PBS solution. The pieces were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 20% fetal bovine serum (FBS) and 1% penicillin-streptomycin. After 3--4 weeks, fibroblast outgrowths from the explants were passaged and cultured in DMEM containing 10% FBS and 1% penicillin-streptomycin.

3.3.. Generation and culture of human iPSCs from human fibroblasts {#S6}
------------------------------------------------------------------

Fibroblasts from AD-HIES patients were reprogrammed with the Human STEMCCA Cre-Excisable Constitutive Polycistronic (OKSM) Lentivirus reprogramming kit (Millipore). iPSC colonies were collected 21 days post-transduction, maintained in full E8 medium at 37°C with 5% CO^2^ and passaged with 0.5mM EDTA every 3--5 days ([@R4]).

3.4.. Immunofluorescence staining {#S7}
---------------------------------

Cells were fixed in 4% paraformaldehyde for 10 minutes, permeabilized with 0.3% Triton X-100 for 30 min and then blocked with donkey 5% serum. They were then incubated with primary antibodies NANOG, OCT4, SSEA4, and TRA-1--60 ([Table 3](#T3){ref-type="table"}) overnight at 4°C, washed and incubated with fluorophore-tagged secondary antibodies for 1 h at room temperature. After PBS wash, DAPI was added for nuclear staining before capturing images with a fluorescence microscope (Zeiss).

3.5.. Embryoid Body (EB) formation {#S8}
----------------------------------

EB formation was performed as described with minor modifications. Briefly, iPSCs were dissociated into small clumps by EDTA/PBS incubation for 5 minutes and transferred into ultra-low attachment plates (Corning) to allow for self-aggregation. Cells were cultured at 37C, 20% CO~2~ in KnockOut DMEM (ThermoFisher Scientific) supplemented with 10% FBS. The media was replaced every other day and EBs were analyzed at differentiation day 10.

3.6.. Gene Expression Analysis {#S9}
------------------------------

Endogenous mRNA expression levels of genes were determined by RT-PCR in iPSCs and EB at differentiation day 10. RT-PCR was performed with SYBR Green premix (Bio-rad) and mRNA copy number was quantified relative to 18 S. All assays were run in duplicate and primers are shown in [Table 3](#T3){ref-type="table"}. Data are represented as the average ± SEM relative to the mRNA levels found in fibroblasts of each sample. The specificity of the amplified PCR products was confirmed by analysis of the melting curve.

3.7.. Karyotyping assay {#S10}
-----------------------

To exclude introduction of chromosomal abnormalities during the iPSC generation and propagation procedure, cell karyotype was evaluated by the WiCell Research Institute using G-banding metaphase karyotype analysis every 10 cell passages starting at passage 10 and counting 20 metaphase spreads ([supplement 3](#SD3){ref-type="supplementary-material"}).

3.8.. DNA sequencing and STR {#S11}
----------------------------

Genomic DNA was isolated by using DNeasy Blood & Tissue Kit (Qiagen). To amplify the corresponding mutation position in *STAT3,* PCR was performed with specific primers ([Table 3](#T3){ref-type="table"}). Following purification, the PCR products were sent to Eurofins Scientific for sequencing. STR analysis was performed by WiCell Research Institute, which generated a STR profile via the Promega Powerplex® 16 System to verify STR polymorphisms for 15 loci plus amelogenin in genomic DNA extracted from iPSCs and their parental fibroblasts.

3.9.. Mycoplasma detection {#S12}
--------------------------

To ensure iPSC cultures were mycoplasma free, media were collected after culturing for 48 h and tested with the MycoAlert™ Mycoplasma Detection Kit (Lonza).
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  -------------------------------------- -----------------------------------------------------------------------------------------------------------------
  Unique stem cell lines identifier      NIHTVBi011-A
                                         NIHTVBi012-A
                                         NIHTVBi013-A
  Alternative names of stem cell lines   AD-HIES3
                                         AD-HIES4
                                         AD-HIES5
  Institution                            National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, Maryland, USA
  Contact information of distributor     Manfred Boehm; <boehmm@nhlbi.nih.gov> and Guibin Chen; <chengb@nhlbi.nhi.gov>
  Type of cell lines                     iPSC
  Origin                                 Human
  Cell Source                            Dermal fibroblasts
  Clonality                              Clonal cell lines
  Method of reprogramming                Lentiviral vectors containing the transcription factors Oct4, Klf4, Sox2 and c-MYC
  Multiline rationale                    Lines derived from the five patients
  Gene modification                      Yes
  Type of modification                   Hereditary
  Associated disease                     None
  Gene/locus                             STAT3, 17q21.2
  Method of modification                 N/A
  Name of transgene or resistance        N/A
  Inducible/constitutive system          N/A
  Date archived/stock date               September 2012
  Cell line repository/bank              N/A
  Ethical approval                       National Institutes of Health Ethics Committee (Approval Number: 10-H-0126)
  -------------------------------------- -----------------------------------------------------------------------------------------------------------------

###### 

Summary of three AD-HIES patients with a STAT3 mutation

  iPSC line names   Abbreviation in figures   Gender   Age (years)   Ethnicity           Genotype of locus   Mutation     Protein Mutation   Disease
  ----------------- ------------------------- -------- ------------- ------------------- ------------------- ------------ ------------------ ---------
  NIHTVBi011-A      HIES3                     M        24            European-American   *STAT3*, 17q21.2    1915 C-G     P639A              AD-HIES
  NIHTVBi012-A      HIES4                     F        56            European-American   *STAT3*, 17q21.2    1954 G-A     E652K              AD-HIES
  NIHTVBi013-A      HIES5                     M        49            European-American   *STAT3*, 17q21.2    1387delGTG   del V463           AD-HIES

###### 

Characterization and validation

  Classification                        Test                                                 Result                                                                                                                     Data
  ------------------------------------- ---------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  Morphology                            Phase-contrast microscope                            Normal                                                                                                                     [Figure 1A](#F1){ref-type="fig"}
  Phenotype                             Qualitative analysis (immunofluorescence staining)   Expression of pluripotency markers: OCT4, NANOG, SSEA4 and TRA-1--60                                                       [Figure 1A](#F1){ref-type="fig"}
                                        Quantitative analysis (RT-qPCR)                      Expression of pluripotency markers: *NANOG, SOX2*, and *OCT3/4*                                                            [Figure 1C](#F1){ref-type="fig"}
  Genotype                              Karyotype (G-banding) and resolution                 46,XX or 46,XY; resolution 450--500 bands                                                                                  [Figure 1D](#F1){ref-type="fig"}
  Identity                              Microsatellite PCR OR STR analysis                   Not performed                                                                                                              N/A
                                                                                             15 sites tested, 100% match                                                                                                Supplementary file
  Mutation analysis (IF APPLICABLE)     DNA sequencing                                       STAT3 mutation                                                                                                             [Figure 1B](#F1){ref-type="fig"}
                                        Southern blot OR WGS                                 Not performed                                                                                                              N/A
  Microbiology and virology             *Mycoplasma* testing by luminescence                 Negative                                                                                                                   Supplementary file
  Differentiation potential             EB formation assay                                   Differentiating cells are expression of *RUNX1, AFP*, and *NES*; iPSCs were able to differentiate into three germ layers   [Figure 1C](#F1){ref-type="fig"}
  Donor screening (OPTIONAL)            HIV1 + HIV2, hepatitis B virus, hepatitis C virus    Not performed                                                                                                              N/A
  Genotype additional info (OPTIONAL)   Blood group genotyping                               Not performed                                                                                                              N/A
                                        HLA tissue typing                                    Not performed                                                                                                              N/A

###### 

Reagents. Antibodies used for immunocytochemistry

  ---------------------- ------------------------------------ ---------- --------------------------- --------- -------------
                         Antibody                             Dilution   Company                     Cat\#     RRID
                                                                                                               
  Primary antibodies     Rabbit anti-OCT4                     1:100      Cell Signaling Technology   2750      AB_823583
                         Mouse anti-NANOG                     1:100      Cell Signaling Technology   4893      AB_10548762
                         Mouse anti-SSEA4                     1:100      MilliporeSigma              MAB4304   AB_177629
                         Mouse anti-TRA-1--60                 1:150      MilliporeSigma              MAB4360   AB_2119183
  Secondary antibodies   Alexa Fluor 594 Donkey anti-rabbit   1:300      Life Technologies           A21207    AB_141637
                         Alexa Fluor 594 Donkey anti-mouse    1:300      Life Technologies           A21203    AB_141633
                         Alexa Fluor 488 Donkey anti-mouse    1:300      Life Technologies           A21202    AB_141607
                         Alexa Fluor 555 Goat anti-mouse      1:300      Life Technologies           A21426    AB_2535847
                                                                                                               
  ---------------------- ------------------------------------ ---------- --------------------------- --------- -------------
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